A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer
暂无分享,去创建一个
Pierre Validire | Yudi Pawitan | Angel Porgador | Jonathan R. Dry | Ioana Berindan-Neagoe | Eitan Rubin | Johan Hansson | Razelle Kurzrock | Jordi Rodon | Serge Koscielny | Khee Chee Soo | Jean-Yves Blay | Philippe Vielh | Robert Dann | Gary Palmer | John Mendelsohn | Gerald Batist | Marco A. Pierotti | Michel Ducreux | Gilles Vassal | Jean-Yves Scoazec | J. Blay | Y. Pawitan | R. Schilsky | K. Soo | R. Berger | P. Validire | A. Eggermont | M. Ducreux | A. Carvalho | R. Kurzrock | V. Lazar | G. Vassal | G. Batist | J. Dry | J. Soria | I. Berindan‐Neagoe | S. Koscielny | M. Pierotti | I. Osman | J. Scoazec | J. Mendelsohn | R. Buller | A. Porgador | J. Hansson | T. le Chevalier | A. Irimie | D. Ye | H. Nechushtan | P. Morice | P. Vielh | E. Rubin | L. Lacroix | S. Depil | J. Martini | J. Gómez-Navarro | A. Yver | Zhengyin Kan | J. Kehren | J. Rodon | S. Galbraith | M. Lehnert | A. Onn | C. Pramesh | B. Besse | A. Mortlock | R. Dann | J. Haspel | S. Laderman | A. Al Omari | Trent T Haywood | C. Bresson | Hilario Mata | Jack J. Lee | K. Jhaveri | G. Meurice | G. Palmer | Karina Eterovic | M. Rothenberg | W. Ki Hong | Jean-Charles Soria | Vladimir Lazar | Guillaume Meurice | Ludovic Lacroix | Alexander Eggermont | Benjamin Besse | Alexandru Irimie | Iman Osman | Komal Jhaveri | Richard L. Schilsky | Raanan Berger | Thierry Le Chevalier | Catherine Bresson | Jean-François Martini | Amir Onn | Philippe Morice | Manfred Lehnert | Richard Buller | Hovav Nechushtan | Andre L. Carvalho | Mace Rothenberg | Andrew Mortlock | Susan Galbraith | Jeanne Kehren | Stephane Depil | Jesus Gomez-Navarro | Antoine Yver | Zhengyin Kan | CS Pramesh | Ding-wei Ye | Joel Haspel | Steve Laderman | Amal S. Al Omari | Trent Haywood | Hilario Mata | Karina Agda Eterovic | Waun Ki Hong | J. Rodón
[1] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[2] The eMERGE Clinical Annotation Working Group,et al. Expression profiling — best practices for data generation and interpretation in clinical trials , 2004 .
[3] Guidel Ines,et al. Expression profiling — best practices for data generation and interpretation in clinical trials , 2004, Nature Reviews Genetics.
[4] Gordon K Smyth,et al. Statistical Applications in Genetics and Molecular Biology Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments , 2011 .
[5] Alona Muzikansky,et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] S. Koscielny. Why Most Gene Expression Signatures of Tumors Have Not Been Useful in the Clinic , 2010, Science Translational Medicine.
[7] Jeffrey W. Clark,et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. , 2010, The New England journal of medicine.
[8] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[9] A. Tolcher,et al. The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer , 2012, Clinical Cancer Research.
[10] P. A. Futreal,et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.
[11] Razelle Kurzrock,et al. Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative , 2012, Clinical Cancer Research.
[12] S. Elledge,et al. Cumulative Haploinsufficiency and Triplosensitivity Drive Aneuploidy Patterns and Shape the Cancer Genome , 2013, Cell.
[13] Pierre Validire,et al. Integrated molecular portrait of non-small cell lung cancers , 2013, BMC Medical Genomics.
[14] K. Kinzler,et al. Cancer Genome Landscapes , 2013, Science.
[15] Javier Munoz,et al. Molecular profiling and the reclassification of cancer: divide and conquer. , 2013, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.
[16] A. Shaw,et al. Molecular Pathways Molecular Pathways : Resistance to Kinase Inhibitors and Implications for Therapeutic Strategies , 2014 .
[17] Alexander M. Menzies,et al. Dabrafenib and Trametinib, Alone and in Combination for BRAF-Mutant Metastatic Melanoma , 2014, Clinical Cancer Research.
[18] R. Yelensky,et al. Unique molecular signatures as a hallmark of patients with metastatic breast cancer: Implications for current treatment paradigms , 2014, Oncotarget.
[19] A. Frigessi,et al. Principles and methods of integrative genomic analyses in cancer , 2014, Nature Reviews Cancer.
[20] R. Kurzrock,et al. Toxicity of targeted therapy: Implications for response and impact of genetic polymorphisms. , 2014, Cancer treatment reviews.
[21] Steven J. M. Jones,et al. Comprehensive molecular profiling of lung adenocarcinoma , 2014, Nature.